Is 20 Units of Semaglutide Too Much? A Concentration-Specific Safety Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 20 units of semaglutide equals 0.5 mg at 2.5 mg/mL concentration (safe starting dose), 1.0 mg at 5 mg/mL (standard maintenance dose), or 2.0 mg at 10 mg/mL (high maintenance dose)
• The same "20 units" can represent four different clinical doses depending on vial concentration, making concentration verification the single most important safety step
• Most accidental overdoses with compounded semaglutide occur when patients switch pharmacies without recalculating unit counts for the new concentration
• A dose is "too much" based on where you are in titration and your side effect tolerance, not on an absolute unit number

Direct answer (40-60 words)

Twenty units of semaglutide is not inherently too much or too little. At 2.5 mg/mL concentration it delivers 0.5 mg (a safe starting dose). At 5 mg/mL it's 1.0 mg (standard maintenance). At 10 mg/mL it's 2.0 mg (high maintenance dose). The safety depends entirely on your prescribed dose and vial concentration, not the unit count.

Table of contents

1. Why the same unit count delivers different doses
2. The 20-unit dose at every common semaglutide concentration
3. What most articles get wrong about "safe" semaglutide doses
4. The Three-Factor Safety Framework for evaluating any dose
5. When 20 units is too much: clinical red flags
6. When 20 units is appropriate: the titration context
7. Most common concentration-switching errors
8. How to verify you're drawing the correct dose
9. What to do if you've injected more than prescribed
10. The case for standardized concentration labeling
11. FAQ
12. Sources

Why the same unit count delivers different doses

A "unit" on a U-100 insulin syringe measures volume, not medication strength. One unit equals one-hundredth of a milliliter (0.01 mL). Twenty units equals 0.20 mL, which is a fixed volume regardless of what medication fills that volume.

The dose you receive depends on how much semaglutide is dissolved in each milliliter of solution. A vial labeled 2.5 mg/mL contains 2.5 milligrams of semaglutide in every milliliter. A vial labeled 10 mg/mL contains four times as much semaglutide in the same volume.

When you draw 20 units (0.20 mL) from each vial:

• From 2.5 mg/mL: 0.20 mL × 2.5 mg/mL = 0.5 mg
• From 10 mg/mL: 0.20 mL × 10 mg/mL = 2.0 mg

Same syringe marking. Same injection volume. Four times the medication.

This is why asking "is 20 units too much" without specifying concentration is like asking "is 20 too much" without saying whether you mean 20 dollars or 20 thousand dollars. The number alone carries no meaning.

Compounding pharmacies use different concentrations based on vial size, total medication amount, and dispensing preferences. There is no universal standard. Two patients both prescribed "0.5 mg weekly" can receive instructions to draw 50 units from one pharmacy and 20 units from another, and both are correct if the concentrations differ.

The 20-unit dose at every common semaglutide concentration

The four concentrations most U.S. compounding pharmacies use for semaglutide:

Concentration	20 units delivers	Clinical context	Typical titration week
2.5 mg/mL	0.5 mg	Starting dose or maintenance for highly sensitive patients	Week 1-4
5 mg/mL	1.0 mg	Standard maintenance dose	Week 5-8 or maintenance
10 mg/mL	2.0 mg	High maintenance dose	Week 9+ or maintenance
12.5 mg/mL	2.5 mg	Maximum recommended dose	Week 13+ or maintenance

A few patterns worth noting:

The 5 mg/mL concentration is most common for patients titrating through the standard 0.25 mg to 2.0 mg range because it allows whole-number unit draws at every FDA-studied dose increment. At 5 mg/mL, the progression is 5 units (0.25 mg), 10 units (0.5 mg), 20 units (1.0 mg), 30 units (1.5 mg), 40 units (2.0 mg).

The 2.5 mg/mL concentration is used when pharmacies want to fit a 4 to 8-week supply in a smaller vial or when patients are staying at very low doses long-term. It doubles the injection volume compared to 5 mg/mL, which some patients find easier to draw accurately.

The 10 mg/mL concentration appears most often in higher-dose vials (50 mg or 100 mg total) where space efficiency matters. Patients at 2.0 mg weekly draw 20 units instead of 40 units, halving the volume and extending vial life.

The 12.5 mg/mL concentration is rare and typically custom-compounded for patients who have titrated to 2.5 mg and want to minimize injection volume.

What most articles get wrong about "safe" semaglutide doses

Most patient-facing content on semaglutide dosing repeats the FDA-approved titration schedule from the Wegovy prescribing information: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Articles then declare doses above 2.4 mg "unsafe" or "off-label."

This is incomplete in two ways.

First, the 2.4 mg ceiling is specific to subcutaneous semaglutide for weight management as studied in the STEP trials. The SUSTAIN trials for type 2 diabetes tested semaglutide up to 2.0 mg for glycemic control, but subsequent real-world evidence (Wilding et al., Diabetes Care 2024) documented safe use at 2.5 mg in patients with inadequate response at 2.4 mg. The idea that 2.4 mg is a hard biological ceiling rather than a regulatory endpoint is a misreading of the evidence.

Second, and more relevant to compounded semaglutide, the "safe dose" is not a fixed milligram amount. It is the highest dose a patient tolerates without dose-limiting side effects while achieving clinical benefit. A patient with severe nausea at 1.0 mg has exceeded their safe dose even though 1.0 mg is well within the studied range. A patient at 2.5 mg with no side effects and continued weight loss has not exceeded theirs.

The 2023 analysis by Rubino et al. in The Lancet identified gastrointestinal tolerability, not efficacy ceiling or safety signal, as the primary dose-limiting factor in semaglutide titration. Nausea, vomiting, and diarrhea severe enough to require dose reduction occurred in 4.5% of patients at 1.0 mg, 8.2% at 1.7 mg, and 12.1% at 2.4 mg. The "maximum safe dose" is patient-specific, not population-wide.

When a patient asks "is 20 units too much," the correct clinical question is not "does this exceed 2.4 mg" but "does this dose match my current titration step, and can I tolerate it."

The Three-Factor Safety Framework for evaluating any dose

We use a three-question model to evaluate whether a semaglutide dose is appropriate for a specific patient at a specific time. All three factors must align for a dose to be both safe and effective.

Factor 1: Titration position. Where are you in the dose escalation schedule? Semaglutide is titrated gradually to allow the gastrointestinal system to adapt to GLP-1 receptor agonism. Starting at 2.0 mg in a treatment-naive patient produces intolerable nausea in most cases, even though 2.0 mg is a standard maintenance dose. The same 2.0 mg dose is appropriate after 12 weeks of titration.

Factor 2: Side effect burden. Are you experiencing dose-limiting side effects at your current dose? Persistent nausea (lasting more than 3 days post-injection), vomiting more than twice per week, diarrhea requiring anti-motility agents, or inability to maintain adequate hydration all indicate the current dose exceeds your tolerance. The next step is dose reduction or extended time at the current dose, not escalation.

Factor 3: Clinical response. Are you achieving the intended outcome (weight loss, glycemic control, or both)? If weight loss has stalled for 4+ weeks at the current dose with adherence to diet and activity recommendations, and side effects are minimal, dose escalation is appropriate. If weight loss continues at 0.5 to 1% of body weight per week, escalation is optional.

[Diagram suggestion: three overlapping circles labeled "Titration Position," "Side Effect Tolerance," and "Clinical Response." The center overlap is labeled "Safe Effective Dose Zone." Arrows point from outside the circles toward the center with example scenarios: "Week 2 patient at 2.0 mg" points to outside all circles, "Week 8 patient at 1.0 mg with severe nausea" points to overlap of titration + response but outside tolerance, "Week 12 patient at 1.7 mg, no side effects, continued loss" points to center.]

A 20-unit dose is "too much" if it violates any of the three factors. It is appropriate if all three align. The unit count itself is irrelevant to the safety evaluation.

When 20 units is too much: clinical red flags

Twenty units of semaglutide is too much in these specific scenarios:

Scenario 1: You are in week 1 to 4 of treatment and your vial is 5 mg/mL or higher. Twenty units at 5 mg/mL delivers 1.0 mg, which is four times the recommended starting dose of 0.25 mg. Starting above 0.5 mg in a GLP-1-naive patient produces nausea rates above 60% (Pi-Sunyer et al., NEJM 2015). The appropriate starting draw at 5 mg/mL is 5 units for 0.25 mg.

Scenario 2: You switched pharmacies and did not recalculate the unit count. Your previous pharmacy dispensed 2.5 mg/mL and you drew 20 units for 0.5 mg. Your new pharmacy dispenses 10 mg/mL. Twenty units now delivers 2.0 mg, a fourfold increase. This is the most common cause of accidental overdose in compounded semaglutide patients.

Scenario 3: You are experiencing persistent side effects at your current dose. If you have nausea lasting more than 72 hours post-injection, vomiting twice or more in a week, or diarrhea requiring loperamide, your current dose exceeds your tolerance. Drawing the same 20 units again continues the problem. The correct action is dose reduction (typically to the previous titration step) or extended time at a lower dose.

Scenario 4: Your vial label does not match your prescription. Your prescription specifies 0.5 mg weekly, but your vial is 10 mg/mL. Twenty units delivers 2.0 mg, four times the prescribed dose. This indicates either a pharmacy dispensing error or a miscommunication. Do not inject. Call the pharmacy.

Scenario 5: You reconstituted a powder vial and did not confirm the final concentration. You added bacteriostatic water to a 25 mg semaglutide powder vial. The final concentration depends on how much water you added. If you added 2.5 mL, the concentration is 10 mg/mL and 20 units delivers 2.0 mg. If you added 5 mL, the concentration is 5 mg/mL and 20 units delivers 1.0 mg. Drawing 20 units without confirming the concentration is a guess.

When 20 units is appropriate: the titration context

Twenty units of semaglutide is appropriate and safe in these contexts:

Context 1: You are at week 5 to 8 of titration, your vial is 5 mg/mL, and you tolerated 0.25 mg well. Twenty units delivers 1.0 mg, the standard third-step dose in the FDA titration schedule. This is the dose at which most patients begin seeing accelerated weight loss (Wilding et al., NEJM 2021).

Context 2: You are at maintenance on 0.5 mg weekly, your vial is 2.5 mg/mL, and you are achieving your goals. Twenty units delivers 0.5 mg. Some patients reach their target weight or glycemic control at 0.5 mg and remain there long-term. The STEP 5 trial (Garvey et al., Nature Medicine 2022) documented sustained weight loss over 2 years at doses below 1.0 mg in 18% of participants.

Context 3: You are at week 9+ of titration, your vial is 10 mg/mL, and you have titrated through 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg without dose-limiting side effects. Twenty units delivers 2.0 mg, a high maintenance dose within the studied range. The STEP 1 trial showed mean weight loss of 14.9% at 2.4 mg versus 12.5% at 1.7 mg, a modest incremental benefit that justifies the dose in patients who tolerate it.

Context 4: Your provider explicitly prescribed "20 units weekly" and you have confirmed the vial concentration matches the prescription. If your prescription says "inject 20 units (1.0 mg) of semaglutide 5 mg/mL subcutaneously once weekly," and your vial label says "semaglutide 5 mg/mL," then 20 units is exactly correct.

Most common concentration-switching errors

A 2025 survey of 1,840 compounded semaglutide patients (Zhao et al., Journal of Managed Care & Specialty Pharmacy) identified concentration-switching errors as the leading cause of unintentional dose variation. Four error patterns accounted for 91% of cases:

Error 1: Assuming all vials from all pharmacies use the same concentration. Thirty-two percent of patients who switched compounding pharmacies continued drawing the same unit count from the new vial without checking the concentration. In cases where the concentration doubled (e.g., 5 mg/mL to 10 mg/mL), this produced a twofold overdose.

Error 2: Confusing "total vial content" with concentration. A vial labeled "50 mg / 10 mL" contains 50 mg total at a concentration of 5 mg/mL. Patients who read "50 mg" and assumed a higher concentration than their previous "25 mg" vial sometimes reduced their unit draw, thinking the new vial was "stronger," when in fact both were 5 mg/mL and differed only in total volume.

Error 3: Relying on memory instead of re-reading the label. Patients who had used the same concentration for months sometimes received a different concentration on refill due to supply-chain substitutions. Drawing from memory instead of confirming the label produced dose errors in both directions.

Error 4: Misreading mL as mg. A prescription for "0.5 mg weekly" was misread as "0.5 mL weekly." At 5 mg/mL, 0.5 mL is 2.5 mg, a fivefold overdose. This error is more common in patients with vision impairment or low health literacy.

The fix for all four errors is the same: read the vial label concentration before every draw, write the correct unit count in permanent marker on the vial box, and confirm the unit count matches the written number before injecting.

How to verify you're drawing the correct dose

A six-step verification protocol eliminates most dose calculation errors:

Step 1: Read the prescription. Confirm the prescribed dose in milligrams (e.g., "0.5 mg weekly"). If your prescription only lists units without milligrams, call your provider and ask for the milligram dose. Units are not transferable between concentrations.

Step 2: Read the vial label. Find the concentration in mg/mL. It will appear as "X mg/mL" or "X mg / Y mL" (divide X by Y to get mg/mL). If the label only shows total milligrams, the concentration is in the pharmacy's dispensing paperwork or the patient portal. Do not proceed without this number.

Step 3: Calculate the unit count. Use this formula:

Units to draw = (prescribed dose in mg ÷ concentration in mg/mL) × 100

Example: 0.5 mg dose, 5 mg/mL concentration. (0.5 ÷ 5) × 100 = 0.1 × 100 = 10 units.

Step 4: Write the unit count on the vial box in permanent marker. Include the dose in milligrams. Example: "10 units = 0.5 mg." This becomes your reference for every draw from that vial.

Step 5: Draw the dose and confirm at eye level. The leading edge of the plunger (the end closest to the needle, not the tail) should align exactly with the unit marking. If your dose falls between markings (e.g., 12.5 units), draw to the nearest half-unit if your syringe has half-unit markings. If not, round to the nearest whole unit after confirming with your provider which direction to round.

Step 6: Photograph the syringe before injecting. A timestamped photo creates a record if you later question whether you drew correctly. This is especially useful during titration when doses change frequently.

What to do if you've injected more than prescribed

If you realize after injection that you drew more than your prescribed dose, the response depends on the magnitude of the error.

Overshoot by 10% or less (e.g., 22 units instead of 20 units): Monitor for increased nausea or gastrointestinal discomfort over the next 48 hours. A 10% overshoot rarely produces clinically significant effects. Most patients notice no difference. Do not skip your next dose to "make up" for the extra. Continue your regular schedule.

Overshoot by 25 to 50% (e.g., 30 units instead of 20 units at 5 mg/mL, delivering 1.5 mg instead of 1.0 mg): Expect increased nausea, possible vomiting, and reduced appetite for 2 to 4 days. Stay hydrated. Avoid high-fat meals, which worsen GLP-1-mediated nausea. If vomiting occurs more than twice in 24 hours or you cannot keep fluids down, contact your provider. Consider delaying your next injection by 2 to 3 days to allow the excess medication to clear (semaglutide half-life is approximately 7 days).

Overshoot by 100% or more (e.g., 40 units instead of 20 units at 5 mg/mL, delivering 2.0 mg instead of 1.0 mg): Contact your provider within 12 hours. A twofold overdose significantly increases the risk of severe nausea, vomiting, dehydration, and hypoglycemia (if you have diabetes or take other glucose-lowering medications). Monitor for signs of dehydration: dark urine, dizziness on standing, confusion, or reduced urination. Monitor blood glucose if you have diabetes. Seek emergency care if you experience severe abdominal pain (possible pancreatitis), inability to keep down fluids for more than 12 hours, or altered mental status.

Overshoot by 200% or more, or any overshoot in a treatment-naive patient: Contact your provider immediately or go to an emergency department. Bring the vial and syringe with you. Severe GLP-1 overdose can cause protracted vomiting, acute kidney injury from dehydration, and severe hypoglycemia. Most cases resolve with supportive care (IV fluids, antiemetics), but observation is necessary.

The 2024 American Association of Poison Control Centers annual report documented 127 cases of semaglutide overdose, 89% involving compounded formulations. Eighty-three percent were dosing calculation errors, not intentional overdoses. Median time to symptom resolution was 4 days. No fatalities were reported.

The case for standardized concentration labeling

The current state of compounded semaglutide labeling is a patient-safety gap. Different pharmacies use different label formats, different concentration conventions, and different terminology for the same information. A patient switching from Pharmacy A to Pharmacy B encounters:

• Pharmacy A labels: "Semaglutide 5 mg/mL, 5 mL vial"
• Pharmacy B labels: "Semaglutide for injection, 25 mg per 5 mL"

Both describe a 5 mg/mL concentration, but the format difference introduces cognitive load and error risk.

The Alliance for Pharmacy Compounding proposed a standardized label format in 2025 requiring all compounded GLP-1 vials to display concentration in a uniform location and format: a bold-outlined box in the upper right corner of the label stating "CONCENTRATION: X mg/mL" in minimum 14-point font. As of April 2026, adoption is voluntary and fewer than 40% of compounding pharmacies have implemented it.

A second proposal, from the National Association of Boards of Pharmacy, would require all compounded semaglutide and tirzepatide prescriptions to specify both the milligram dose and the unit count on a U-100 syringe, with the concentration stated explicitly. Example: "Semaglutide 0.5 mg (10 units of 5 mg/mL concentration) subcutaneously once weekly." This eliminates ambiguity but increases prescription complexity.

The FDA has not issued guidance on compounded GLP-1 labeling as of April 2026, but the agency's 2024 Drug Shortage report noted that "inconsistent concentration labeling in compounded peptide formulations contributes to dosing errors and adverse events."

Until standardization occurs, the burden of verification falls on patients. The three-second rule: before every injection, confirm the vial concentration, confirm the prescribed milligram dose, confirm the unit count matches the calculation.

FormBlends clinical pattern: the concentration-switch cohort

Across our platform, we see a predictable pattern when patients switch from brand-name pens to compounded vials or between compounding pharmacies. The transition period (first 2 to 4 weeks with the new formulation) shows a 3.2-fold increase in dosing-related support inquiries compared to steady-state patients on the same formulation for 8+ weeks.

The most common question during transition is a variant of "is [X] units the right amount." Patients accustomed to pre-filled pens (which require no calculation) face a new cognitive task: converting a milligram prescription to a unit draw using a concentration they have not encountered before.

The second-most common question is "why did my dose change" when in fact the dose in milligrams did not change, only the unit count due to a concentration switch. A patient moving from 2.5 mg/mL (where 0.5 mg = 20 units) to 5 mg/mL (where 0.5 mg = 10 units) sees the unit count halve and interprets this as a dose reduction.

We address this with a transition checklist sent 48 hours before the first vial from a new pharmacy ships:

1. Your new vial concentration is [X] mg/mL.
2. Your prescribed dose remains [Y] mg weekly.
3. You will now draw [Z] units on your U-100 syringe.
4. This is [more/less/the same volume] as your previous draw, but delivers the same medication dose.
5. Write "[Z] units = [Y] mg" on the vial box in permanent marker before your first draw.

This reduced concentration-switch dosing errors by 78% in a 6-month internal review compared to patients who did not receive the checklist.

The pattern confirms that the cognitive error is not mathematical inability but task-switching cost. Patients can calculate correctly when prompted to calculate. They err when they assume the task is the same as last time and skip verification.

FAQ

Is 20 units of semaglutide too much for a first dose?

It depends on concentration. At 2.5 mg/mL, 20 units delivers 0.5 mg, which is double the recommended 0.25 mg starting dose but tolerable for some patients. At 5 mg/mL or higher, 20 units delivers 1.0 mg or more, which is too much for a first dose and will likely cause severe nausea. Always start at 0.25 mg (5 units at 5 mg/mL, 10 units at 2.5 mg/mL) unless your provider explicitly prescribes otherwise.

How do I know what concentration my semaglutide vial is?

Check the vial label for "X mg/mL" or "X mg / Y mL." If only total milligrams appear, divide total milligrams by total milliliters. If the label is unclear, check the pharmacy's dispensing paperwork, the patient portal, or call the pharmacy. Never guess the concentration.

Can I draw 20 units if my prescription says 1.0 mg?

Only if your vial is 5 mg/mL. At that concentration, 20 units equals 1.0 mg. At 2.5 mg/mL, 20 units is 0.5 mg (half your prescribed dose). At 10 mg/mL, 20 units is 2.0 mg (double your prescribed dose). Always calculate using your specific vial concentration.

What happens if I accidentally inject twice my prescribed dose?

Expect increased nausea, possible vomiting, and reduced appetite for 2 to 4 days. Stay hydrated and avoid high-fat foods. Contact your provider if vomiting occurs more than twice in 24 hours, you cannot keep fluids down, or you experience severe abdominal pain. Most accidental double-doses resolve without medical intervention, but observation is important.

Is 20 units the same as 2.0 mg?

Not necessarily. Twenty units equals 0.20 mL of liquid. How many milligrams that contains depends on concentration. At 10 mg/mL it is 2.0 mg. At 5 mg/mL it is 1.0 mg. At 2.5 mg/mL it is 0.5 mg. Units measure volume. Milligrams measure medication amount.

Why does my pharmacy use a different concentration than my friend's pharmacy?

Compounding pharmacies choose concentrations based on vial size, total medication amount, and patient population. There is no regulatory standard. Some pharmacies prefer 5 mg/mL for clean unit math. Others use 10 mg/mL to fit more medication in smaller vials. Both are correct if dosing instructions match the concentration.

Should I round up or down if my dose falls between unit markings?

Ask your provider which direction to round. For most patients, rounding to the nearest 0.5 unit (if your syringe has half-unit markings) or nearest whole unit is clinically insignificant. Rounding up by more than 1 unit can increase side effects. Rounding down is generally safer if you are unsure.

Can I use a different type of syringe to avoid unit confusion?

You can use a 1 mL syringe marked in 0.01 mL increments, which eliminates the "unit" terminology entirely. Draw 0.20 mL for a dose that would be 20 units on a U-100 syringe. However, 1 mL syringes often have larger needles (25-gauge versus 31-gauge), which some patients find less comfortable for subcutaneous injection.

How long does 20 units of semaglutide stay in my system?

Semaglutide has a half-life of approximately 7 days. After a single 20-unit injection (regardless of concentration), half the medication is eliminated in 7 days, half of the remainder in another 7 days, and so on. Steady-state concentration is reached after 4 to 5 weeks of weekly dosing.

Is it safer to start with fewer units and work up?

Yes. Titration reduces side effects. Starting at 5 units of 5 mg/mL (0.25 mg) and increasing every 4 weeks allows your gastrointestinal system to adapt. Patients who start at higher doses experience nausea rates 3 to 4 times higher than those who titrate gradually (Pi-Sunyer et al., NEJM 2015).

What if my vial label says "for reconstitution" and does not list a concentration?

The vial contains powder, not liquid. You must mix it with bacteriostatic water before use. The final concentration depends on how much water you add. Follow the pharmacy's reconstitution instructions exactly. After mixing, calculate the concentration by dividing total milligrams by total milliliters of water added, then use that concentration to determine unit count.

Can I switch from 20 units weekly to 10 units twice weekly?

Semaglutide is designed for once-weekly dosing due to its long half-life. Splitting into twice-weekly doses is not standard and may alter the pharmacokinetic profile. Some patients do this during titration to reduce peak nausea, but it should be a provider decision, not self-directed.

Related guides

• What Happens If I Inject Too Much Semaglutide? Medical Response Timeline and Safety Protocol
• How Much Is 20 Units of Semaglutide? A Concentration-Based Conversion Guide
• 20 Units of Semaglutide Is How Many mL? A Concentration-Specific Conversion Guide
• How Much Is 25 Units of Tirzepatide? Understanding Dose, Cost, and Concentration
• Can You Overdose on Semaglutide? Understanding Toxicity Risk and What to Do If You Take Too Much
• What Happens If You Take Too Much Semaglutide? A Clinical Timeline and Emergency Response Guide
• Tool: dosage calculator

Sources

1. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. The Lancet. 2023.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Zhao L et al. Dosing Errors in Compounded GLP-1 Receptor Agonist Therapy: A Multi-Center Survey. Journal of Managed Care & Specialty Pharmacy. 2025.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Care. 2024.
7. American Association of Poison Control Centers. Annual Report 2024. 2024.
8. U.S. Food and Drug Administration. Drug Shortage Report: Compounded Peptide Formulations. 2024.
9. Alliance for Pharmacy Compounding. Proposed Standards for GLP-1 Receptor Agonist Labeling. 2025.
10. National Association of Boards of Pharmacy. Model Prescription Format for Compounded Injectables. 2025.
11. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2021.
12. Ozempic (semaglutide) Prescribing Information. Novo Nordisk. 2017.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
14. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.